Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 4/20 | 0.56 |
| ▸ | PLAU | P00749 | 4/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 9/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.51 |
| ▸ | ATP4A | P20648 | 1/20 | 0.48 |
| ▸ | ATP4B | P51164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21017182 | 0.86 | PLG (0.51) | PLGPLAUHDAC3HDAC4HDAC1 | |
| SCHEMBL5579984 | 0.83 | CHEK1 (0.59) | CHEK2 | |
| SCHEMBL21018408 | 0.83 | CHEK2 (0.61) | PLGPLAUHDAC3HDAC4HDAC1 | |
| SCHEMBL21017203 | 0.82 | ACHE (0.60) | PLGPLAUHDAC3HDAC4HDAC1 | |
| SCHEMBL20982723 | 0.82 | CHEK2 (0.61) | PLGPLAUHDAC3HDAC4HDAC1 | |
| SCHEMBL21017881 | 0.81 | PLG (0.53) | PLGPLAUHDAC3HDAC4HDAC1 | |
| SCHEMBL9306624 | 0.80 | HPSE (0.52) | CHEK2 | |
| SCHEMBL465492 | 0.80 | ACHE (0.75) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL465477 | 0.80 | NPC1 (0.56) | PLGPLAUHDAC3HDAC4HDAC1 | |
| SCHEMBL13305839 | 0.79 | PLG (0.60) | PLGPLAUHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194981-B1 | BISBENZIMIDAZOLES AS ANTIMALARIAL AGENTS | UNIV MONS HAINAUT (BE) | 2011-11-23 | — | — | EP | disclosed |
| US-20100160402-A1 | Bisbenzimidazoles as antimalarial agents | XAVIER UNIVERSITY OF LOUISIANA | 2010-06-24 | — | — | US | disclosed |
| US-20100160402-A1 | Bisbenzimidazoles as antimalarial agents | XAVIER UNIVERSITY OF LOUISIANA | 2010-06-24 | — | — | US | disclosed |
| US-20100160402-A1 | Bisbenzimidazoles as antimalarial agents | XAVIER UNIVERSITY OF LOUISIANA | 2010-06-24 | — | — | US | disclosed |
| EP-2194981-A1 | BISBENZIMIDAZOLES AS ANTIMALARIAL AGENTS | Université de Mons-Hainaut (BE) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009043902-A1 | BISBENZIMIDAZOLES AS ANTIMALARIAL AGENTS | UNIVERSITE DE MONS HAINAUT (BE) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009043902-A1 | BISBENZIMIDAZOLES AS ANTIMALARIAL AGENTS | UNIVERSITE DE MONS HAINAUT (BE) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160402-A1 | Bisbenzimidazoles as antimalarial agents | NQO2, SQOR, CPS1 | PLG 3016/4885PLAU 4421/4885HDAC3 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.